RxDoctor Payments Data

Christopher Trojanovich, MD

Internal Medicine · Boulder, CONPI 1518087915

Payments from drug & device makers

$1,669in general payments, 2019–2025

Across 39 payments — averaging $42.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$581
  • Teva Pharmaceuticals USA, Inc.$237
  • Boston Scientific$189
  • W. L. Gore & Associates, Inc.$142
  • Lilly USA, LLC$122
  • Amarin Pharma, Inc.$121
  • plus $278 from 11 others

What the payments were for

  • Food & beverage$1,669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,669 in reported general payments places this provider in the 85th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$236,983
Medicare patients
274
Services billed
2,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$117,667
Repatha SureclickEvolocumab38$33,974
Repatha PushtronexEvolocumab25$26,840
XareltoRivaroxaban23$26,119
JardianceEmpagliflozin16$21,170
MounjaroTirzepatide12$14,231
LinzessLinaclotide12$10,436
Praluent PenAlirocumab19$9,276
Icosapent Ethyl12$6,088
Celecoxib104$6,079
Rosuvastatin Calcium370$5,666
SynthroidLevothyroxine Sodium66$4,831
Breo ElliptaFluticasone/Vilanterol12$4,631
ValacyclovirValacyclovir Hcl31$3,167
Levothyroxine Sodium219$2,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Synthroid$32$15,26778 claims
Lilly USA, LLCMounjaro$122$14,23112 claims
GSKBreo Ellipta$14$4,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →